RxDoctor Payments Data

Matthew Wietrzykowski, MD

Internal Medicine · Hamtramck, MINPI 1528040979

Payments from drug & device makers

$480in general payments, 2019–2025

Across 26 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$90
  • Lilly USA, LLC$70
  • Genentech USA, Inc.$59
  • AstraZeneca$55
  • Pfizer$47
  • Abbott$38
  • plus $122 from 7 others

What the payments were for

  • Food & beverage$45795%
  • Education$235%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$480 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$45,352
Medicare patients
169
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin331$306,340
OzempicSemaglutide249$295,841
FarxigaDapagliflozin Propanediol155$132,627
JanuviaSitagliptin Phosphate139$110,402
TrulicityDulaglutide55$60,984
EliquisApixaban64$51,240
XareltoRivaroxaban50$48,004
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$38,722
RybelsusSemaglutide16$33,138
MounjaroTirzepatide32$32,289
VascepaIcosapent Ethyl67$28,087
EntrestoSacubitril/Valsartan33$26,094
TopamaxTopiramate17$23,226
Bydureon BciseExenatide Microspheres20$22,574
LinzessLinaclotide25$18,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$90$328,979265 claims
Boehringer IngelheimJardiance, Tradjenta$16$317,653349 claims
AstraZenecaFarxiga, Brilinta, Symbicort$55$143,584190 claims
Lilly USA, LLCTrulicity, Mounjaro$70$93,27387 claims
PfizerEliquis$47$51,24064 claims
AbbVieLinzess$25$18,71125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Hamtramck

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →